Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- G7 Health Ministers to Discuss AMR Measures at Upcoming Kobe Confab
September 5, 2016
- METI Seeks 7.2 Bil. Yen for Drug Discovery, 3.5 Bil. for Regenerative Medicine
September 2, 2016
- Panel OKs Iridosteresis, 7 Other Illnesses as Designated Intractable Diseases
September 1, 2016
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- “Untreated” Erased from Viekirax’s Add’l Indication: Sept. 9 Panel Meeting
August 31, 2016
- Lilly Drops Listing of Taltz amid Pricing Fuss, Wants to Deliver Drug without Restrictions
August 31, 2016
- MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November
August 30, 2016
- MHLW Unveils FY2017 Budget Request, 105.8 Bil. Yen Sought for Healthcare Innovation
August 29, 2016
- MHLW Requests Extension of R&D Tax Credit for “High-Level Investment”
August 29, 2016
- MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs
August 29, 2016
- AZ’s Ticagrelor, BI’s Triple Combo to Take Another Stab to Clear MHLW Committee
August 26, 2016
- MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7
August 26, 2016
- MHLW Grants Orphan Status to Crizotinib, 3 Other Drugs
August 26, 2016
- Innovative Drugs Are Not “Villain,” Kamoya Laments
August 25, 2016
- Chuikyo Subcommittee Effectively Kicks Off Debates on FY2018 Reform, with Focus on Pricy Meds
August 25, 2016
- Discussions on Opdivo’s Special Pricing Measure Get Underway at Chuikyo Subcommittee
August 25, 2016
- After Taltz Given High Price, MHLW to Push Use of Other Psoriasis Drugs; Revision to Foreign Price Adjustment Eyed
August 25, 2016
- MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
August 24, 2016
- MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
August 24, 2016
- Chuikyo OKs Praluent, 8 Other APIs for Listing on Aug. 31
August 24, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…